腎芽腫治療藥市場:各類型，各藥物類型，各流通管道，各地區- 規模，佔有率，展望，機會分析，2022年～2030年

Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月29日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場動態

各種組織和研究人員為開發腎母細胞瘤治療方法而增加的研發活動預計將在預測期內推動市場增長。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球腎芽腫治療藥市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球腎芽腫治療藥市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球腎芽腫治療藥市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球腎芽腫治療藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy. Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.

Market Dynamics

Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.

Key features of the study:

This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nephroblastoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Detailed Segmentation:

Global Nephroblastoma Treatment Market, By Type:
- Favorable histology
- Anaplastic histology
Global Nephroblastoma Treatment Market, By Drug Type:
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
Global Nephroblastoma Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Nephroblastoma Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Type
- Favorable histology
- Anaplastic histology
  - By Drug Type
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
  - By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Merck & Co., Inc.
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Recordati Rare Diseases
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Actiza Pharmaceutical Private Limited
- Teva Pharmaceutical Industries Ltd.
- Alvogen
- Accord Healthcare Ireland Ltd.
- Baxter
- Amneal Pharmaceuticals LLC.
- Cadila Pharmaceuticals Ltd.
- Company Highlights
- Xediton Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
PEST Analysis
Epidemiology
Product Launch/Approvals

4. Global Nephroblastoma Treatment Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Demand and Supply Analysis

5. Global Nephroblastoma Treatment Market, By Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Favorable histology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Anaplastic histology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Dactinomycin (Cosmegen)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Doxorubicin (Adriamycin)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Vincristine (Vincasar PFS, Oncovin)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Cyclophosphamide (Cytoxan, Neosar)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Etoposide (Toposar, VePesid)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Irinotecan (Camptosar)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Nephroblastoma Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Recordati Rare Diseases
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Actiza Pharmaceutical Private Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alvogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Accord Healthcare Ireland Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amneal Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cadila Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Xediton Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies